Format
Items per page
Sort by

Send to:

Choose Destination

Results: 19

1.

Diagnosis and classification of primary sclerosing cholangitis.

Yimam KK, Bowlus CL.

Autoimmun Rev. 2014 Apr-May;13(4-5):445-50. doi: 10.1016/j.autrev.2014.01.040. Epub 2014 Jan 11. Review.

PMID:
24424180
2.

Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance.

Navaneethan U, Jegadeesan R, Gutierrez NG, Venkatesh PG, Hammel JP, Shen B, Kiran RP.

J Crohns Colitis. 2013 Dec 15;7(12):e684-91. doi: 10.1016/j.crohns.2013.06.006. Epub 2013 Jul 31.

3.

Small duct autoimmune sclerosing cholangitis and Crohn colitis in a 10-year-old child. A case report and review of the literature.

Larsen EP, Bayat A, Vyberg M.

Diagn Pathol. 2012 Aug 14;7:100. doi: 10.1186/1746-1596-7-100. Review.

4.

Ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing cholangitis for prevention of colon cancer: a meta-analysis.

Ashraf I, Choudhary A, Arif M, Matteson ML, Hammad HT, Puli SR, Bechtold ML.

Indian J Gastroenterol. 2012 Apr;31(2):69-74. doi: 10.1007/s12664-012-0175-3. Epub 2012 Apr 14.

PMID:
22528343
5.

PSC, AIH and overlap syndrome in inflammatory bowel disease.

Trivedi PJ, Chapman RW.

Clin Res Hepatol Gastroenterol. 2012 Oct;36(5):420-36. doi: 10.1016/j.clinre.2011.10.007. Epub 2012 Feb 3. Review.

PMID:
22306055
6.

Review article: colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease.

Torres J, Pineton de Chambrun G, Itzkowitz S, Sachar DB, Colombel JF.

Aliment Pharmacol Ther. 2011 Sep;34(5):497-508. doi: 10.1111/j.1365-2036.2011.04753.x. Epub 2011 Jun 22. Review.

PMID:
21692821
7.

Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies.

Triantafillidis JK, Nasioulas G, Kosmidis PA.

Anticancer Res. 2009 Jul;29(7):2727-37. Review.

8.

Colorectal cancer in inflammatory bowel disease.

Potack J, Itzkowitz SH.

Gut Liver. 2008 Sep;2(2):61-73. doi: 10.5009/gnl.2008.2.2.61. Epub 2008 Sep 30.

9.

Cancer in inflammatory bowel disease.

Xie J, Itzkowitz SH.

World J Gastroenterol. 2008 Jan 21;14(3):378-89. Review.

10.

Colorectal cancer in inflammatory bowel disease: molecular and clinical considerations.

Rubin DT, Parekh N.

Curr Treat Options Gastroenterol. 2006 Jun;9(3):211-20.

PMID:
16901385
11.
12.

[Ulcerative colitis. Cancer prevention].

Schmiegel W, Pox C, Kroesen A.

Z Gastroenterol. 2004 Sep;42(9):1014-8. German. No abstract available.

PMID:
15455276
13.

Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis.

Pardi DS, Loftus EV Jr, Kremers WK, Keach J, Lindor KD.

Gastroenterology. 2003 Apr;124(4):889-93.

PMID:
12671884
14.

Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid.

Bernstein CN, Eaden J, Steinhart AH, Munkholm P, Gordon PH.

Inflamm Bowel Dis. 2002 Sep;8(5):356-61. Review.

PMID:
12479651
15.

Prevention of colon cancer with ursodiol in ulcerative colitis.

Kim HS.

Inflamm Bowel Dis. 2001 Aug;7(3):279-80. No abstract available.

PMID:
11515858
16.

Chemoprevention in ulcerative colitis: narrowing the gap between clinical practice and research.

Hawk ET, Viner JL.

Ann Intern Med. 2001 Jan 16;134(2):158-60. No abstract available.

PMID:
11177320
17.

Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis.

Tung BY, Emond MJ, Haggitt RC, Bronner MP, Kimmey MB, Kowdley KV, Brentnall TA.

Ann Intern Med. 2001 Jan 16;134(2):89-95.

PMID:
11177311
18.

Current concepts in primary sclerosing cholangitis.

Wiesner RH.

Mayo Clin Proc. 1994 Oct;69(10):969-82. Review.

PMID:
7934194
19.

Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis.

Stiehl A.

Ann Med. 1994 Oct;26(5):345-9. Review.

PMID:
7826595
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk